Skip to Content

'
Stefan Faderl

Present Title & Affiliation

Primary Appointment

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Clinical Interests

Dr. Faderl came to M.D. Anderson in 1996. Dr. Faderl graduated from Ludwig Maximilian Medical School in Munich, Germany in 1990 and received his medical/academic degree (magna cum laude) from the same institution in 1994. Dr. Faderl is board certified in Internal Medicine and Medical Oncology. He specializes in acute and chronic leukemias. His main areas of interest include acute lymphoblastic leukemias (ALL), acute myeloid leukemias (AML), chronic lymphocytic leukemia (CLL) and its variants, as well as chronic myeloid leukemias (CML). Dr. Faderl has authored and co-authored many abstracts, articles in peer-reviewed journals and book chapters. He serves on numerous editorial boards and is a member of several professional societies such as the American Society of Hematology (ASH), the American College of Physicians (ACP), and the American Society of Clinical Oncology. Contact information for Dr. Faderl is: (713) 745-4613 e-mail: sfaderl@mdanderson.org.

Education & Training

Degree-Granting Education

1990 Ludwig-Maximilians University Medical School, Munich, Germany, MD

Board Certifications

1/1999 Medical Oncology
1/1996 American Board of Internal Medicine

Experience/Service

Academic Appointments

Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2005-8/2011

Institutional Committee Activities

Member, Institutional Review Board, 9/2008-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. J Clin Oncol 30(8):820-9, 3/2012. e-Pub 2/2012. PMID: 22331955.
2. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. e-Pub 1/2012. PMID: 22282348.
3. Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer 118(3):722-728, 2012. e-Pub 7/2011. PMID: 21751197.
4. Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S, Shan J, Hendrie PC, Pagel JM, Shustov AR, Stirewalt DL, Faderl S, Harrington E, Estey EH. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol 155(2):182-9, 10/2011. e-Pub 8/2011. PMID: 21848522.
5. Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z, Ravandi F, Faderl S, Kantarjian H, Garcia-Manero G. Implications of discrepancy in morphological diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood 118(17):4690-3, 10/2011. e-Pub 8/2011. PMID: 21868570.
6. Faderl S, Bueso-Ramos C, Liu Z, Pal A, Bornmann W, Ciurea DV, Harris D, Hazan-Halevy I, Kantarjian HM, Estrov Z. Kit inhibitor APcK110 extends survival in an AML xenograft mouse model. Invest New Drugs 29(5):1094-7, 10/2011. e-Pub 6/2010. PMID: 20517635.
7. Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Koller C, Challagundla P, York S, Brandt M, Luthra R, Burger J, Thomas D, Keating M, Kantarjian H. Phase II study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 118(14):3818-23, 10/2011. e-Pub 8/2011. PMID: 21821712.
8. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Cyclophosphamide, fludarabine, rituximab and alemtuzumab (CFAR) as salvage therapy for heavily pre-treated patients with chronic lymphocytic leukemia. Blood 118(8):2085-93, 8/2011. e-Pub 6/2011. PMID: 21670470.
9. Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab (CFAR) for high-risk chronic lymphocytic leukemia. Blood 118(8):2062-2068, 8/2011. e-Pub 7/2011. PMID: 21750315.
10. Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, Faderl S, Garcia-Manero G, Borthakur G, Cortes J. Impact of Treatment End Point Definitions on Perceived Differences in Long-Term Outcome With Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. J Clin Oncol 29(23):3173-3178, 8/2011. e-Pub 7/2011. PMID: 21747082.
11. Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Persistence of Cytogenetic Abnormalities at Complete Remission After Induction in Patients With Acute Myeloid Leukemia: Prognostic Significance and the Potential Role of Allogeneic Stem-Cell Transplantation. J Clin Oncol 29(18):2507-13, 6/2011. e-Pub 5/2011. PMID: 21555694.
12. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117(11):3016-24, 3/2011. e-Pub 1/2011. PMID: 21245487.
13. Faderl S, Thomas DA, O'Brien S, Ravandi F, Garcia-Manero G, Borthakur G, Ferrajoli A, Verstovsek S, Ayoubi M, Rytting M, Feliu J, Kantarjian HM. Augmented Hyper-CVAD Based on Dose-Intensified Vincristine, Dexamethasone, and Asparaginase in Adult Acute Lymphoblastic Leukemia Salvage Therapy. Clin Lymphoma Myeloma Leuk 11(1):54-9, 2/2011. PMID: 21454191.
14. Faderl S, Ferrajoli A, Wierda W, O'Brien S, Lerner S, Keating MJ. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer 116(10). e-Pub 3/2010. PMID: 20225334.
15. Faderl S, O'Brien S, Pui C-H, Stock W, Wetzler M, Hoelzer D, Kantarjian H. Adult acute lymphoblastic leukemia - concepts and strategies. Cancer 116(5):1165-1176, 2010. PMID: 20101737.
16. Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 years. Leuk Res 34(3):284-288, 2010. PMID: 19646755.
17. Faderl S, Ferrajoli A, Frankfurt O, Pettitt A. Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy. Leukemia 23(3):457-466, 5/2009. PMID: 18987653.
18. Faderl S. Last exit clofarabine? Leuk Lymphoma 50(12):1907-1908, 2009. PMID: 20001243.
19. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as frontline therapy for patients age >= 60 years with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112(5):1638-1645, 3/2008. PMID: 18565853.
20. Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 113(8):2090-2096, 2008. PMID: 18756533.
21. Faderl S, Ferrajoli A, Harris D, Van Q, Kantarjian HM, Estrov Z. Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Leuk Res 31:91-5, 1/2007. PMID: 16828865.
22. Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'Brien S, Sheng S, Esseltine DL, Keating MJ. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 107(5):916-24, 9/2006. PMID: 16832816.
Other Articles
1. Ferrajoli A, O'Brien SM, Faderl S, Wierda WG, Reuben JM, Keating MJ. Lenalidomide: An emerging option in chronic lymphocytic leukemia. Haemagologica Meeting Reports 3(3):103-105, 2009.

Last updated: 2/14/2012